Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 4/20 | 0.45 |
| ▸ | MAOA | P21397 | 4/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.35 |
| ▸ | WDR5 | P61964 | 14/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.32 |
| ▸ | CALML3 | P27482 | 1/20 | 0.32 |
| ▸ | SDHA | P31040 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9930736 | 0.93 | MAOA (0.37) | MAOBMAOACYP2C19WDR5 | |
| SCHEMBL9968695 | 0.93 | MAOA (0.37) | MAOBMAOACYP2C19WDR5 | |
| SCHEMBL14069647 | 0.93 | MAOA (0.37) | MAOBMAOACYP2C19WDR5 | |
| SCHEMBL9964846 | 0.90 | MAOB (0.49) | MAOBMAOACYP2C19KCNH2WDR5 | |
| SCHEMBL9930158 | 0.90 | WDR5 (0.32) | MAOBMAOACYP2C19WDR5 | |
| SCHEMBL9930041 | 0.89 | MAOB (0.47) | MAOBMAOACYP2C19KCNH2WDR5 | |
| SCHEMBL14069657 | 0.88 | WDR5 (0.31) | MAOBMAOACYP2C19WDR5 | |
| SCHEMBL9930226 | 0.88 | MAOB (0.47) | MAOBMAOACYP2C19KCNH2WDR5 | |
| SCHEMBL14069386 | 0.88 | MAOB (0.47) | MAOBMAOACYP2C19KCNH2WDR5 | |
| SCHEMBL9930109 | 0.86 | WDR5 (0.33) | MAOBMAOACYP2C19WDR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120157434-A1 | Antimicrobial heterocyclic compounds for treatment of bacterial infections | CSO of MicuRx Pharmaceuticals, Inc. | 2012-06-21 | — | — | US | disclosed |
| US-20120157434-A1 | Antimicrobial heterocyclic compounds for treatment of bacterial infections | CSO of MicuRx Pharmaceuticals, Inc. | 2012-06-21 | — | — | US | disclosed |
| US-20120157434-A1 | Antimicrobial heterocyclic compounds for treatment of bacterial infections | CSO of MicuRx Pharmaceuticals, Inc. | 2012-06-21 | — | — | US | disclosed |
| WO-2008108988-A1 | ANTIMICROBIAL HETEROCYCLIC COMPOUNDS FOR TREATMENT OF BACTERIAL INFECTIONS | MICURX PHARMACEUTICALS, INC. (US) | 2008-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157434-A1 | Antimicrobial heterocyclic compounds for treatment of bacterial infections | NISCH, NOD1, NQO1 | MAOB 761/4885MAOA 1058/4885CYP2C19 47/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.